MEDI 491

Drug Profile

MEDI 491

Alternative Names: B19 parvovirus vaccine; Recombinant baculovirus-expressed B19 parvovirus virus-like particle vaccine - MedImmune/NHLBI; Recombinant baculovirus-expressed B19 parvovirus VLP vaccine - MedImmune/NHLBI

Latest Information Update: 21 Jun 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator National Heart, Lung and Blood Institute; National Institutes of Health (USA)
  • Developer Chiron Corporation; MedImmune; National Institutes of Health (USA)
  • Class Viral vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Parvovirus infections

Most Recent Events

  • 19 Jun 2007 MedImmune has been acquired by AstraZeneca
  • 04 Oct 2004 Discontinued - Phase-I for Parvovirus infections in USA (unspecified route)
  • 20 Mar 2003 A phase I study has been added to the adverse events and Viral Infections immunogenicity sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top